Predictive Oncology Inc Financials
This page shows Predictive Oncology Inc (POAI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 was a balance-sheet reset, not a commercial turnaround, with capital replacing customer cash as the business's main funding source.
From FY2024 to FY2025, the big change was financial, not operating: revenue stayed tiny at$125K while operating cash use stayed near-$9.9M . Yet equity recapitalized from-$203K to$47.7M with liabilities roughly flat, so the balance sheet recovered without evidence of a customer-funded turnaround.
The company looks equity-funded rather than debt-funded: liabilities were only about
Near-term liquidity improved, but cash burn still dominates the operating story: cash ended FY2025 at
Financial Health Signals
We are recalculating Predictive Oncology Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Predictive Oncology Inc scores -19.02, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($20.2M) relative to total liabilities ($5.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Predictive Oncology Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Predictive Oncology Inc generates $0.04 in operating cash flow (-$9.9M OCF vs -$233.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Predictive Oncology Inc generated $125K in revenue in fiscal year 2025. This represents an increase of 47.7% from the prior year.
Predictive Oncology Inc's EBITDA was -$180.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1677.4% from the prior year.
Predictive Oncology Inc reported -$233.1M in net income in fiscal year 2025. This represents a decrease of 1740.6% from the prior year.
Cash & Balance Sheet
Predictive Oncology Inc generated -$9.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 2.3% from the prior year.
Predictive Oncology Inc held $10.8M in cash against $0 in long-term debt as of fiscal year 2025.
Predictive Oncology Inc had 4M shares outstanding in fiscal year 2025.
Margins & Returns
Predictive Oncology Inc's gross margin was 42.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 34.3 percentage points from the prior year.
Predictive Oncology Inc's operating margin was -144404.5% in fiscal year 2025, reflecting core business profitability. This is down 132255.4 percentage points from the prior year.
Predictive Oncology Inc's net profit margin was -186053.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 171121.1 percentage points from the prior year.
Predictive Oncology Inc's ROE was -488.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Predictive Oncology Inc invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
POAI Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35K+307.1% | $9K+139.7% | $4K+34.9% | $3K-97.6% | $110K+1154.7% | $9K+125.0% | $4K-94.2% | $67K |
| Cost of Revenue | $3.5M+247.5% | -$2.4M-28239.2% | $8K-54.1% | $18K-99.2% | $2.4M+7679.3% | $31K+175.7% | $11K-19.3% | $14K |
| Gross Profit | -$3.4M-44406.4% | $8K+263.5% | -$5K+69.5% | -$16K+99.3% | -$2.3M-10283.9% | -$22K-203.0% | -$7K-113.6% | $53K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $2.9M-85.2% | $19.6M+650.4% | $2.6M+39.3% | $1.9M+2.6% | $1.8M+18.7% | $1.5M-0.4% | $1.5M-15.3% | $1.8M |
| Operating Income | -$7.7M+95.5% | -$172.7M-5165.1% | -$3.3M-23.3% | -$2.7M-16.3% | -$2.3M-9.1% | -$2.1M+2.9% | -$2.2M+12.3% | -$2.5M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$7.7M | N/A | N/A | -$2.1M+15.2% | -$2.4M-12.6% | -$2.2M+29.9% | -$3.1M+2.7% | -$3.2M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
POAI Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $45.2M-14.5% | $52.9M+1585.8% | $3.1M-8.7% | $3.4M-41.5% | $5.9M+18.0% | $5.0M-33.7% | $7.5M-29.2% | $10.6M |
| Current Assets | $37.6M-12.1% | $42.8M+3774.3% | $1.1M-9.8% | $1.2M-64.9% | $3.5M+56.6% | $2.2M-51.3% | $4.6M-33.7% | $6.9M |
| Cash & Equivalents | $6.9M-35.8% | $10.8M+5839.9% | $182K-64.1% | $506K-83.6% | $3.1M+404.7% | $612K-80.1% | $3.1M-42.3% | $5.3M |
| Inventory | N/A | N/A | $38K-11.0% | $43K-6.7% | $46K0.0% | $46K-90.9% | $504K-11.2% | $568K |
| Accounts Receivable | $659K+1952.7% | $32K+23.5% | $26K+13.3% | $23K-61.6% | $60K+75.2% | $34K-92.6% | $464K+19.8% | $387K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.0M-4.2% | $5.2M-93.6% | $80.6M+1483.2% | $5.1M-15.4% | $6.0M+16.2% | $5.2M-6.4% | $5.5M-14.8% | $6.5M |
| Current Liabilities | $4.2M-0.9% | $4.3M-94.6% | $79.5M+1967.1% | $3.8M-16.6% | $4.6M+28.3% | $3.6M-5.9% | $3.8M-17.4% | $4.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $40.3M-15.6% | $47.7M+161.6% | -$77.4M-4583.0% | -$1.7M-1034.1% | -$146K+28.0% | -$203K-110.3% | $2.0M-52.0% | $4.1M |
| Retained Earnings | -$421.2M-1.9% | -$413.5M-57.5% | -$262.6M-42.0% | -$184.9M-1.1% | -$182.9M-1.4% | -$180.4M-1.2% | -$178.3M-1.8% | -$175.2M |
POAI Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.7M+5.0% | -$3.9M-138.3% | -$1.7M+49.8% | -$3.3M-234.2% | -$986K+52.0% | -$2.1M+19.3% | -$2.5M-21.9% | -$2.1M |
| Capital Expenditures | $21K | $0 | $0 | $0 | $0-100.0% | $6K | $0 | $0 |
| Free Cash Flow | -$3.8M+4.4% | -$3.9M-138.3% | -$1.7M+49.8% | -$3.3M-234.2% | -$986K+52.1% | -$2.1M+19.1% | -$2.5M-21.9% | -$2.1M |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$6K |
| Financing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $3.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
POAI Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -9720.5%-9809.8pp | 89.3%+220.3pp | -131.0%+448.4pp | -579.4%+1493.9pp | -2073.3%-1822.8pp | -250.5%-64.4pp | -186.1%-265.5pp | 79.4% |
| Operating Margin | -21887.5%+1968992.6pp | -1990880.1%-1900226.0pp | -90654.1%+8520.7pp | -99174.8%-97101.5pp | -2073.3%+21775.6pp | -23848.9%+31447.8pp | -55296.8%-51632.1pp | -3664.6% |
| Net Margin | -21831.6% | N/A | N/A | -77198.4%-74983.9pp | -2214.5%+22462.4pp | -24676.9%+54532.0pp | -79208.9%-74478.7pp | -4730.1% |
| Return on Equity | -19.1% | N/A | N/A | N/A | N/A | N/A | -157.3%-79.6pp | -77.7% |
| Return on Assets | -17.1% | N/A | N/A | -60.3%-18.6pp | -41.6%+2.0pp | -43.6%-2.4pp | -41.3%-11.2pp | -30.0% |
| Current Ratio | 8.89-1.1 | 10.02+10.0 | 0.01-0.3 | 0.32-0.4 | 0.76+0.1 | 0.62-0.6 | 1.20-0.3 | 1.49 |
| Debt-to-Equity | 0.12+0.0 | 0.11+1.1 | -1.04+2.0 | -3.08+38.2 | -41.25-15.7 | -25.54-28.4 | 2.81+1.2 | 1.59 |
| FCF Margin | -10669.3%+34771.6pp | -45440.9%+271.3pp | -45712.1%+77136.2pp | -122848.3%-121954.6pp | -893.7%+22535.4pp | -23429.1%+41723.8pp | -65152.8%-62048.0pp | -3104.8% |
Similar Companies
Frequently Asked Questions
What is Predictive Oncology Inc's annual revenue?
Predictive Oncology Inc (POAI) reported $125K in total revenue for fiscal year 2025. This represents a 47.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Predictive Oncology Inc's revenue growing?
Predictive Oncology Inc (POAI) revenue grew by 47.7% year-over-year, from $85K to $125K in fiscal year 2025.
Is Predictive Oncology Inc profitable?
No, Predictive Oncology Inc (POAI) reported a net income of -$233.1M in fiscal year 2025, with a net profit margin of -186053.5%.
What is Predictive Oncology Inc's EBITDA?
Predictive Oncology Inc (POAI) had EBITDA of -$180.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Predictive Oncology Inc's gross margin?
Predictive Oncology Inc (POAI) had a gross margin of 42.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Predictive Oncology Inc's operating margin?
Predictive Oncology Inc (POAI) had an operating margin of -144404.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Predictive Oncology Inc's net profit margin?
Predictive Oncology Inc (POAI) had a net profit margin of -186053.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Predictive Oncology Inc's return on equity (ROE)?
Predictive Oncology Inc (POAI) has a return on equity of -488.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Predictive Oncology Inc's free cash flow?
Predictive Oncology Inc (POAI) generated -$9.9M in free cash flow during fiscal year 2025. This represents a 2.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Predictive Oncology Inc's operating cash flow?
Predictive Oncology Inc (POAI) generated -$9.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Predictive Oncology Inc's total assets?
Predictive Oncology Inc (POAI) had $52.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Predictive Oncology Inc's capital expenditures?
Predictive Oncology Inc (POAI) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Predictive Oncology Inc's current ratio?
Predictive Oncology Inc (POAI) had a current ratio of 10.02 as of fiscal year 2025, which is generally considered healthy.
What is Predictive Oncology Inc's debt-to-equity ratio?
Predictive Oncology Inc (POAI) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Predictive Oncology Inc's return on assets (ROA)?
Predictive Oncology Inc (POAI) had a return on assets of -440.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Predictive Oncology Inc's cash runway?
Based on fiscal year 2025 data, Predictive Oncology Inc (POAI) had $10.8M in cash against an annual operating cash burn of $9.9M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Predictive Oncology Inc's Altman Z-Score?
Predictive Oncology Inc (POAI) has an Altman Z-Score of -19.02, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Predictive Oncology Inc's Piotroski F-Score?
Predictive Oncology Inc (POAI) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Predictive Oncology Inc's earnings high quality?
Predictive Oncology Inc (POAI) has an earnings quality ratio of 0.04x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.